Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 1.00 |
| ▸ | F10 | P00742 | 12/20 | 0.84 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.84 |
| ▸ | PRSS2 | P07478 | 12/20 | 0.84 |
| ▸ | PRSS3 | P35030 | 12/20 | 0.84 |
| ▸ | F12 | P00748 | 10/20 | 0.80 |
| ▸ | F7 | P08709 | 10/20 | 0.80 |
| ▸ | F9 | P00740 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17221962 | 1.00 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL20567697 | 0.91 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6921523 | 0.91 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL20484185 | 0.91 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL17236242 | 0.90 | F2 (0.81) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL15298962 | 0.89 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6923431 | 0.88 | F2 (0.79) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6927684 | 0.84 | F2 (0.73) | F2F10PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL16426767 | 0.84 | F2 (1.00) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL17221954 | 0.82 | F2 (0.88) | F2F10PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | claimed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | claimed |
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315141-A1 | Thrombin Inhibitors | F3, F2, F9 | F2 2/4885F10 24/4885PRSS1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.